Trial Profile
A Phase I/II Study of TRC105 in Combination With Sorafenib in Hepatocellular Carcinoma (HCC)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Carotuximab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Jan 2018 Status changed from active, no longer recruiting to completed, as reported in a TRACON Pharmaceuticals Media Release
- 16 Aug 2017 Results published in a TRACON Pharmaceuticals Media Release.
- 02 May 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research